While molnupiravir has promising animal model data, extrapolation in humans may be fraught due to different enzymes involved in activating the nucleotide analogue, experts said. Molnupiravir is in two Phase IIa trials, one in newly hospitalised patients and the other in outpatients, with initial efficacy data expected for both in 1Q. On Monday (25 January), Merck said it was dropping out of the Covid-19 vaccine race and would instead focus on its therapeutic assets, including molnupiravir. In July 2020, Miami, Florida-based Ridgeback and Merck announced they had partnered to advance molnupiravir in Covid-19.
#Dna replication models trial
While targeting Covid-19 patients in the earlier part of the disease spectrum is logical, the trial designs may blur molnupiravir’s clinical value, they said. However, many trial success blind spots persist, limiting efficacy judgment, they added.Įncouraging preclinical data is yet to translate into humans, and there is potential for lingering severe side effects due to molnupiravir’s mutagenic mechanism, experts noted. Ridgeback Biotherapeutics/Merck’s Phase IIa molnupiravir is attractive for outpatient and recently hospitalised Covid-19 patients due to its mechanism and oral administration, experts said.
0 kommentar(er)
